Tetsuro Araki

Tetsuro Araki

Auto-generated profile, based on publicly available information

Tetsuro Araki

Consortium for Safety Assessment using Human iPS Cells (CSAHi). Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in The Journal of Toxicological Sciences
Verified
Journal Article
Closed access
PDF file
YSYosuke Sanuki
Yosuke Sanuki
TATetsuro Araki
Tetsuro Araki
ONOsamu Nakazono
Osamu Nakazono
KTKazuyuki Tsurui
Kazuyuki Tsurui
Drug-induced liver injury is a major cause of safety-related drug-marketing withdrawals. Several drugs have been reported to disrupt mitochondrial function, resulting in hepatotoxicity. The development of a simple and effective in vitro assay to identify the potential for mitochondrial toxicity is thus desired to minimize the risk of causing hepatotoxicity and subsequent drug withdrawal. An in vitro test method called the "glucose-galactose" assay is often used in drug development but requires prior-culture of cells over several passages for mitochondrial adaptation, thereby restricting use of the assay. Here, we report a rapid version of this method with the same predictability as the original method. We found that replacing the glucose in the medium with galactose resulted in HepG2 cells immediately shifting their energy metabolism from glycolysis to oxidative phosphorylation due to drastic energy starvation; in addition, the intracellular concentration of ATP was reduced by mitotoxicants when glucose in the medium was replaced with galactose. Using our proposed rapid method, mitochondrial dysfunction in HepG2 cells can be evaluated by drug exposure for one hour without a pre-culture step. This rapid assay for mitochondrial toxicity may be more suitable for high-throughput screening than the original method at an early stage of drug development.

1 February 2011 in Journal of Biological Chemistry
Verified
Journal Article
Open access
TATetsuro Araki
Tetsuro Araki
MKMorioh Kusakabe
Morioh Kusakabe
ENEisuke Nishida
Eisuke Nishida
Epidermal differentiation in the ventral ectoderm of Xenopus embryos is regulated by the bone morphogenetic protein (BMP) pathway. However, it remains unclear how the BMP pathway is activated and induces the epidermal fate in the ventral ectoderm. Here, we identify a novel player in the BMP pathway that is required for epidermal differentiation during Xenopus early embryonic development. We show that Xenopus EIG121L (xEIG121L) protein, an evolutionarily conserved transmembrane protein, is expressed in the ventral ectoderm at the gastrula and neurula stages. Almost complete knockdown of xEIG121L protein with antisense morpholino oligonucleotides in early Xenopus embryos results in severe developmental defects, including the inhibition of epidermal differentiation and the induction of neural genes. Remarkably, our analysis shows that BMP/Smad1 signaling is severely suppressed in the xEIG121L knockdown ectoderm. Moreover, immunoprecipitation and immunostaining experiments suggest that xEIG121L protein physically interacts, and co-localizes, with BMP receptors. Thus, our results identify a novel regulator of the BMP pathway that has a positive role in BMP signaling and plays an essential role in epidermal differentiation during early embryonic development.

9 June 2020 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
TITomoaki Inoue
Tomoaki Inoue
NINorihiko Iwazaki
Norihiko Iwazaki
TATetsuro Araki
Tetsuro Araki
HHHiroko Hitotsumachi
Hiroko Hitotsumachi
Human hepatocytes are essential cell types for pharmacokinetics and the safety evaluation of pharmaceuticals. However, widely used primary hepatocytes with individual variations in liver function lose those functions rapidly in culture. Hepatic cell lines are convenient to use but have low liver functions. Human-Induced Pluripotent Stem (hiPS) cells can be expanded and potentially differentiated into any cell or tissue, including the liver. HiPS cell-derived Hepatocyte-Like Cells (hiPSHeps) are expected to be extensively used as consistent functional human hepatocytes. Many laboratories are investigating methods of using hiPS cells to differentiate hepatocytes, but the derived cells still have immature liver functions. In this paper, we describe the current uses and limitations of conventional hepatic cells, evaluating the suitability of hiPS-Heps to pharmacokinetics and the safety evaluation of pharmaceuticals, and discuss the potential future use of non-conventional non-monolayer culture methods to derive fully functional hiPS-Heps.

1 January 2016 in Fundamental Toxicological Sciences
Verified
Journal Article
Open access
PDF file
TATetsuro Araki
Tetsuro Araki
NINorihiko Iwazaki
Norihiko Iwazaki
NINaoki Ishiguro
Naoki Ishiguro
ASAtsushi Sakamoto
Atsushi Sakamoto
KNKeisuke Nagata
Keisuke Nagata
TITomoaki Inoue
Tomoaki Inoue
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies

1 March 2015 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Closed access
SKSatoru Kawakami
Satoru Kawakami
TATetsuro Araki
Tetsuro Araki
MNMikio Nakajima
Mikio Nakajima
OKOsamu Kusuoka
Osamu Kusuoka
KUKeisuke Uchida
Keisuke Uchida
KTKazuyuki Tsurui
Kazuyuki Tsurui

30 June 2007 in Gene Expression Patterns
Verified
Journal Article
Closed access
TATetsuro Araki
Tetsuro Araki
MKMorioh Kusakabe
Morioh Kusakabe
ENEisuke Nishida
Eisuke Nishida